Early treatment of heart failure: a non-interventional observational study programme of patients with heart failure and initiated on dapagliflozin (EVOLUTION HF)

被引：0
|
作者：
Rosano, G. [1 ]
Gnesi, M. [2 ]
Mamza, J. B. [3 ]
Morris, T. [3 ]
Chioncel, O. [4 ]
Coombs, S. [5 ]
Eryd, S. Adamsson [6 ]
Metra, M. [7 ]
机构：
[1] San Raffaele Pisana Hosp IRCCS, Rome, Italy
[2] AstraZeneca, Med Evidence, Biopharmaceut Med, Milan, Italy
[3] AstraZeneca, Med & Sci Affairs, Biopharmaceut Med, London, England
[4] Inst Cardiovasc Dis Prof CC Iliescu, Bucharest, Romania
[5] Univ Hosp Sussex NHS Fdn Trust, Sussex Cardiac Ctr, Brighton, England
[6] AstraZeneca, CVRM Evidence BioPharmaceut Med, Gothenburg, Sweden
[7] ASST Spedali Civili, Brescia, Italy
来源：
EUROPEAN JOURNAL OF HEART FAILURE | 2023年 / 25卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：175 / 175
页数：1
相关论文
共 50 条
  • [1] TREATMENT OF HEART FAILURE IN CLINICAL PRACTICE: NON-INTERVENTIONAL OBSERVATIONAL STUDY ON PATIENTS WITH HEART FAILURE TREATED WITH DAPAGLIFLOZIN (EVOLUTION-HF ITALY)
    Orso, F.
    Ameri, P.
    Carugo, S.
    Di Lenarda, A.
    Iacoviello, M.
    Indolfi, C.
    Mortara, A.
    Filardi, P. Perrone
    Ungar, A.
    Volpe, M.
    Volterrani, M.
    Granelli, V.
    Mastromauro, F.
    Pluchinotta, F.
    Gnesi, M.
    Rosano, G.
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2023, 25
  • [2] Clinical characteristics and treatment patterns of new users of dapagliflozin for heart failure with reduced ejection fraction: an observational study programme across 12 countries (EVOLUTION HF)
    Rosano, G.
    Mamza, J. B.
    Morris, T.
    Gnesi, M.
    Pardal, M.
    Isvoranu, M.
    Eryd, S. Adamsson
    Cardoso, J. S.
    Chioncel, O.
    Coombs, S.
    Metra, M.
    EUROPEAN HEART JOURNAL, 2024, 45
  • [3] Burden of disease of heart failure in Asian countries: a retrospective non-interventional study
    Cho, M. C.
    Choi, D. J.
    Wu, T. C.
    Yingchoncharoen, T.
    Ong, T. K.
    Liew, H. B.
    EUROPEAN HEART JOURNAL, 2017, 38 : 308 - 308
  • [4] Dapagliflozin utilization following hospitalization for heart failure: real-world insights from EVOLUTION HF, a multinational, observational study
    Savarese, G.
    Bozkurt, B.
    Eryd, S. Adamsson
    Bodegard, J.
    Lund, L. H.
    Thuresson, M.
    Vardeny, O.
    Kishi, T.
    EUROPEAN HEART JOURNAL, 2022, 43 : 971 - 971
  • [5] Evaluation of dapagliflozin in the treatment of heart failure
    Sotirakos, Sara
    FUTURE CARDIOLOGY, 2020, 17 (03) : 415 - 425
  • [6] An update on dapagliflozin for the treatment of heart failure
    Akinci, B.
    DRUGS OF TODAY, 2021, 57 (02) : 77 - 88
  • [7] Dapagliflozin in the prevention and treatment of heart failure
    Egocheaga, I
    Escobar, C.
    Pallares, V
    Obaya, J. C.
    MEDICINA DE FAMILIA-SEMERGEN, 2021, 47 : 11 - 17
  • [8] Dapagliflozin in heart failure management: Early real world Asian experience (DEFEND HF study)
    Quah, W. J.
    Chan, J. A. W.
    Koh, H. B.
    Ashari, A.
    Ong, S. H.
    Teoh, C. K.
    Ghazi, A. Mohd
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2022, 369 : 26 - 27
  • [9] EFFECTS OF DAPAGLIFLOZIN IN PATIENTS WITH HEART FAILURE
    Abdullaev, Sherzod
    Sharapov, Olimkhon
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2022, 37 : I462 - I462
  • [10] Real-world Characteristics of Patients With Heart Failure in China: Baseline Results From The Retrospective Non-interventional Nationwide Study (REPRESENT-HF)
    Zhou, Jingmin
    Li, Xinli
    Dong, Yugang
    Yang, Jiefu
    Huo, Yong
    Ge, Junbo
    CIRCULATION, 2019, 140
12345